The clinical study of the budesonide/formoterol combination drug additional dosage in the perioperative period in a lung cancer patient with COPD.
Not Applicable
Recruiting
- Conditions
- on-small cell lung cancer patients with COPD.
- Registration Number
- JPRN-UMIN000011462
- Lead Sponsor
- Hamamatsu University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patient that there is ICS/LABA mixing medicine in pre-administering within four weeks 2)Patient where exacerbation of COPD was admitted within four weeks 3)Patient that there is past of hypersensitivity in atropine, the kind edge material or tiotropium, budesonide or formoterol 4)Patient who has chronic ailments of lungs, heart, kidney, liver, and blood, etc. 5)Patient who has previous history of adrenal cortical insufficiency or accentuation syndrome 6)Patient who has glaucoma 7)Patient who has dysuria such as dysuria by enlarged prostate 8)Case who judged doctor in charge targets and it is improper
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Exacerbation rate of 12 weeks after the operation. (The extension of hospitalization, the infectious disease or the additional dosage of the antibiotic and administering a systemic steroid and the decrease in the respiratory function; The sum total of each event that falls below the predictive value by 10% or more at the time of 12 of the week of after the operation is divided in the population).
- Secondary Outcome Measures
Name Time Method